Coagulation biomarkers in critically ill patients

Crit Care Clin. 2011 Apr;27(2):281-97. doi: 10.1016/j.ccc.2010.12.009.


This article discusses coagulation biomarkers in critically ill patients where coagulation abnormalities occur frequently and may have a major impact on the outcome. An adequate explanation for the cause is important, since many underlying disorders may require specific treatment and supportive therapy directed at the underlying condition. Deficiencies in platelets and coagulation factors in bleeding patients or patients at risk for bleeding can be achieved by transfusion of platelet concentrate or plasma products, respectively. Prohemostatic treatment may be beneficial in case of severe bleeding, whereas restoring physiological anticoagulant pathways may be helpful in patients with sepsis and disseminated intravascular coagulation.

MeSH terms

  • Biomarkers
  • Blood Coagulation Disorders / blood*
  • Blood Coagulation Disorders / diagnosis*
  • Blood Coagulation Factor Inhibitors / blood*
  • Critical Illness*
  • Diagnosis, Differential
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Fibrinolysis
  • Humans
  • Partial Thromboplastin Time
  • Platelet Count
  • Prothrombin Time
  • Thrombelastography
  • Thrombocytopenia


  • Biomarkers
  • Blood Coagulation Factor Inhibitors
  • Fibrin Fibrinogen Degradation Products